2,5,7-trihydroxy-3-(4-hydroxyphenyl)chromen-4-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: 2,5,7-trihydroxy-3-(4-hydroxyphenyl)chromen-4-one
• 化学式: C₁₅H₁₀O₆
• 分子量: 286.24
• InChiKey: XWHJDPLZZUQKSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• COMPOSITION FOR USE IN THE TREATMENT OF MENOPAUSE PROBLEMS/DISORDERS AND IN THE TREATMENT OF GENERAL AGING OF THE ORGANISM
  申请人：Paladin Pharma S.p.A.

  公开号：EP2672964A1

  公开（公告）日：2013-12-18
• COMPOSITION FOR USE IN THE TREATMENT OF MENOPAUSE PROBLEMS/DISORDERS
  申请人：Paladin Pharma S.p.A.

  公开号：EP2672964B1

  公开（公告）日：2016-06-01
• Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof
  申请人：Maurya Rakesh

  公开号：US20090221690A1

  公开（公告）日：2009-09-03

  Osteoporosis is one of the major problems in our aging society. Osteoporosis results in bone fracture in older members of the population, especially in post-menopausal women. In traditional medicine, there are many natural crude drugs that have the potential for use to treat bone diseases. So far, there is no report in literature on anti-osteoporosis (bone forming) activity of Butea species. It was thought to study the anti-osteoporotic activity of this plant. Thus, the present invention provides a pharmaceutical composition from the extracts of Butea monosperma for prevention or treatment of bone disorders, process of preparation and use thereof.
• US7084265B1
  申请人：——

  公开号：US7084265B1

  公开（公告）日：2006-08-01
• [EN] COMPOSITION FOR USE IN THE TREATMENT OF MENOPAUSE PROBLEMS/DISORDERS AND IN THE TREATMENT OF GENERAL AGING OF THE ORGANISM.<br/>[FR] COMPOSITION DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE PROBLÈMES/TROUBLES DE LA MÉNOPAUSE ET DANS LE TRAITEMENT DU VIEILLISSEMENT GÉNÉRAL DE L'ORGANISME
  申请人：PALADIN PHARMA S P A

  公开号：WO2012107905A1

  公开（公告）日：2012-08-16

  The invention concerns a composition for the prevention and/or the treatment of menopausal syndrome and/or of aging comprising an association of an equolbased active metabolite of daidzein with resveratrol, in an edible carrier or excipient. The invention composition may be in the form of a nutraceutical or pharmaceutical preparation.